Clinical Trial Update: A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study [Phase 3]

View source ↗

Summary

This entry summarizes Phase 3 core and 24-month open-label extension studies evaluating the efficacy and safety of intravitreal ranibizumab for diabetic macular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis | Conditions: Diabetic Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2011-04-19